INmune Bio Q1 net loss $6.5M; cash $51M; advances DN-TNF and INKmune trials

Inmune Bio, Inc.

2023-Q1 EPS reported -$0.36 revenue$38,000

Net loss $6.5M vs $6.9M YoY; R&D $4.1M, G&A $2.3M.
Cash and equivalents $51.0M at March 31, 2023; 17.9M shares outstanding.
FDA provides clear pathway to lift clinical hold on AD Phase 2 by year-end.
IND filed for INKmune in mCRPC; Phase 1 in MDS/AML enrolling at three sites.
Top-line XPro Alzheimer's results expected 2H 2024; NIH-funded depression trial pending FDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Inmune Bio, Inc. reported the quarter ended March 31, 2023 results: net income approximately $6.5 million.

Period: the quarter ended March 31, 2023
Net income: approximately $6.5 million
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for the quarter ended March 31, 2023 was approximately $6.5 million, compared to approximately $6.9 million during the quarter ended March 31, 2022.

View on SEC.gov

Browse all earnings releases →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-036402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.